What is Zacks Research’s Estimate for IOVA Q3 Earnings?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Analysts at Zacks Research boosted their Q3 2026 earnings per share estimates for Iovance Biotherapeutics in a research note issued to investors on Wednesday, August 26th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings per share of ($0.13) for the quarter, up from their prior estimate of ($0.14). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($0.48) per share. Zacks Research also issued estimates for Iovance Biotherapeutics’ Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.56) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at ($0.10) EPS, FY2027 earnings at ($0.44) EPS, Q1 2028 earnings at ($0.07) EPS, Q2 2028 earnings at ($0.02) EPS and FY2028 earnings at ($0.07) EPS.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. The business had revenue of $198.63 million for the quarter, compared to analyst estimates of $87.83 million. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%.The company’s revenue was up 65.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.33) earnings per share.

A number of other brokerages have also issued reports on IOVA. Chardan Capital cut their price target on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Citigroup reissued an “outperform” rating on shares of Iovance Biotherapeutics in a report on Friday, August 7th. Robert W. Baird set a $6.00 target price on Iovance Biotherapeutics in a research report on Friday, August 7th. UBS Group raised their target price on Iovance Biotherapeutics from $4.00 to $7.00 and gave the stock a “neutral” rating in a research note on Thursday, August 20th. Finally, Barclays lifted their price target on Iovance Biotherapeutics from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Seven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $8.89.

Iovance Biotherapeutics Stock Up 2.2%

IOVA stock opened at $8.26 on Friday. The firm has a 50 day moving average of $5.39 and a 200 day moving average of $4.29. The stock has a market capitalization of $3.74 billion, a PE ratio of -11.31 and a beta of 0.71. Iovance Biotherapeutics has a 52 week low of $1.76 and a 52 week high of $9.36.

Institutional Trading of Iovance Biotherapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Granite Investment Partners LLC purchased a new stake in shares of Iovance Biotherapeutics in the 4th quarter valued at $29,000. Motley Fool Asset Management LLC purchased a new position in shares of Iovance Biotherapeutics during the fourth quarter worth $29,000. M&T Bank Corp purchased a new position in shares of Iovance Biotherapeutics during the fourth quarter worth $31,000. SBI Securities Co. Ltd. lifted its position in Iovance Biotherapeutics by 169.1% during the fourth quarter. SBI Securities Co. Ltd. now owns 11,568 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 7,269 shares during the period. Finally, KBC Group NV acquired a new position in Iovance Biotherapeutics during the first quarter valued at $34,000. 77.03% of the stock is currently owned by institutional investors and hedge funds.

Iovance Biotherapeutics News Summary

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Price target raised to $10: Analysts increased their price target for IOVA to $10.00, implying potential upside from the stock’s $8.26 opening price and reinforcing recent positive momentum. Iovance Biotherapeutics Price Target Raised to $10.00
• Positive Sentiment: Several earnings estimates improved: Zacks Research raised its 2026 EPS forecast to a loss of $0.56 from $0.62, improved its third-quarter 2026 estimate to a loss of $0.13 from $0.14, and lifted longer-term estimates for the second quarter of 2027, second quarter of 2028 and full-year 2028. The FY2028 forecast improved to a loss of $0.07 from $0.10, suggesting expectations for narrowing losses over time.
• Neutral Sentiment: Positive oncology-sector exposure: Zacks highlighted Iovance alongside other biotechnology companies as a potential beneficiary of advances in cancer care and pipeline development. The commentary supports investor interest but did not announce a new approval, trial result or partnership. Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
• Negative Sentiment: Other forecasts were reduced: Zacks cut estimates for 2026 fourth-quarter EPS, 2027 first-, third- and fourth-quarter EPS, full-year 2027 EPS, and 2028 first-quarter EPS. The largest annual revision was for FY2027, moving to a loss of $0.44 from $0.36, highlighting continued uncertainty around the pace of profitability.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.